Salk Institute

Technologies Available for Licensing

IKK2: A Central Player in Allergic Reactions

Inventors: Kotaro Suzuki and Inder Verma
Potential Uses: Drug Discovery and Development, Allergic Reactions

Methods of identifying IKK2 activators or inhibitors for regulation of mast cell degranulation

Allergic diseases, such as atropic rhinitis, asthma, and atropic dermatitis are modulated mainly by mast cells. Cross-linking of the high affinity receptor for IgE on these cells activates intracellular signaling pathways that lead to degranulation and the release of histamine and other preformed chemical mediators. Most of the currently used anti-allergic drugs are inhibitors of these mediators because these bioactive mediators are thought to lead to allergic inflammation. However, existing anti-allergic drugs have an insufficient therapeutic effect on disease.

Recently, we have discovered the importance of IKK2 in early phase allergic reactions. IKK2 in mast cells mediates IgE-induced degranulation by phosphorylating SNAP-23 in an NF-kB-independent manner, leading to anaphylactic reactions. This suggests that molecules or biologics that inhibit IKK2 would be excellent therapeutic agents for anaphylactic reactions.

Salk No: S08005
Patent Status: PCT Application filed August 2009
Publications: Cell 134: 485-495 (August 2008)
Press Release: Multi-tasking molecule holds key to allergic reactions
License Terms: Exclusive, Partially Exclusive, Nonexclusive license negotiable
Contact: Michelle Booden, Ph.D., Director of Licensing, 858.453.4100 x1612,

Get Involved

Sign up for our email newsletter

Fill out my online form.
Salk Institute for Biological Studies
Street: 10010 N Torrey Pines Rd
City: La Jolla, CA 92037
Phone: 858.453.4100
Charity Navigator Rating
  • Salk Twitter
  • Salk LinkedIn
  • Salk Facebook
  • Salk Instagram
  • Salk Google+
  • Salk YouTube
  • Salk RSS Feed
© Copyright 2015 Salk Institute for Biological Studies | Privacy Policy About Scientists & Research News & Media Events Support